Analysis | Metabolite Name | Measured Value | Units | Cell Type | Stimulation |
---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 17137 | Peak area | HAHA | TNF-alpha |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 21991 | Peak area | PAK | TNF-alpha |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 22129 | Peak area | HAHA | Untreated |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 26779 | Peak area | HAHA | IFN-G |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 31186 | Peak area | PAK | Untreated |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 31871 | Peak area | BS4 | IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 36699 | Peak area | HAHA | IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 39059 | Peak area | BS4 | TNF-alpha |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 41193 | Peak area | PAK | IFN-G |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 43334 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 46070 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 51356 | Peak area | PAK | IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 54171 | Peak area | BS4 | Untreated |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | 70724 | Peak area | BS4 | IFN-G |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+CL)- | Peak area | HAHA | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | 22288 | Peak area | BS4 | TNF-alpha |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | 23441 | Peak area | PAK | IFN-G |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | 30226 | Peak area | BS4 | Untreated |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | 44560 | Peak area | BS4 | IFN-G |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | 55107 | Peak area | BS4 | IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | 64960 | Peak area | PAK | Untreated |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | 75358 | Peak area | PAK | IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | 76738 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | Peak area | BS4 | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | Peak area | HAHA | IFN-G | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | Peak area | HAHA | IL-17A | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | Peak area | HAHA | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | Peak area | HAHA | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | Peak area | HAHA | Untreated | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M-H)- | Peak area | PAK | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | 1565 | Peak area | BS4 | IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | 5268 | Peak area | BS4 | Untreated |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | 34440 | Peak area | BS4 | TNF-alpha |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | 50935 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | 52445 | Peak area | PAK | TNF-alpha |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | 54489 | Peak area | PAK | Untreated |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | 64164 | Peak area | PAK | IL-17A |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | Peak area | BS4 | IFN-G | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | Peak area | BS4 | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | Peak area | HAHA | IFN-G | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | Peak area | HAHA | IL-17A | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | Peak area | HAHA | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | Peak area | HAHA | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | Peak area | HAHA | Untreated | |
Reversed phase NEGATIVE ION MODE | URIDINE (CAS# 58-96-8); (M+HCOO)- | Peak area | PAK | IFN-G |